Sutro Biopharma, Inc.STRONASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -49.66% | -86.98% | +33.76% | +147.98% | +13.77% |
| Gross Profit Growth | -49.66% | -86.98% | +54.70% | +166.54% | +13.77% |
| EBITDA Growth | +0.00% | -203.83% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | -251.23% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | -333.20% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | -272.55% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | -272.55% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +35.39% | +35.27% | +35.22% | +4.13% | +3.44% |
| Weighted Average Shares Diluted Growth | +35.39% | +35.27% | +35.22% | +4.13% | +3.44% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -609.79% | +0.00% | -573.02% | +0.00% |
| Free Cash Flow Growth | +0.00% | -676.41% | +0.00% | -615.12% | +0.00% |
| Receivables Growth | -59.97% | -76.12% | -56.67% | +15.09% | -41.07% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +4.66% | -17.74% | -20.32% | -46.35% | -53.60% |
| Book Value per Share Growth | -26.88% | -77.97% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -34.87% | -31.16% | -23.77% | +728.16% | -28.97% |
| R&D Expense Growth | +36.00% | +32.12% | -9.28% | -38.21% | -35.83% |
| SG&A Expenses Growth | -6.14% | -46.26% | +21.10% | -16.39% | -39.01% |